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(3) reported a significant close correlation between the 2-D
echocardiographic LV mass and the necropsy LV mass, and we
followed the recommendation of the Committee on M-Mode
Standardization of the American Society of Echocardiography (2).
We believe that M-mode echocardiography with 2-D monitoring
in a blinded fashion was sufficient to evaluate LV mass and LV
function, especially in nonischemic CHF patients who were the
subjects of this study and who had diffuse LV hypokinesis and no
focal hypertrophy by 2-D echocardiography. Actually, we have
reported that there was a close correlation between LV mass by
echocardiography and LV mass by magnetic resonance imaging in
patients with essential hypertension (4).
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Increased von Willebrand Factor
in the Endocardium as a Local
Predisposing Factor for Thrombogenesis
in Overloaded Human Atrial Appendage
We read with great interest the article by Fukuchi et al. (1),
describing immunohistochemical evidence of increased expression
of von Willebrand factor (vWF) in the endocardium of “overload-
ed” human atrial appendages, as a possible mechanism of intra-
atrial thrombogenesis. They describe an increase in atrial endocar-
dial vWF expression in patients with mitral valve disease (MVD)
and heart failure, but state that the level of vWF expression is
unaffected by the presence of atrial fibrillation (AF). Although we
welcome the work as an advancement in our understanding of
intra-atrial thrombogenesis, we respectfully suggest that Fukuchi
et al. (1) may have understated the potential importance of AF and
vWF expression in the endocardium of the left atrial appendage
(LAA).
Fukuchi et al. (1) did not show a difference in vWF expression
by direct comparison of the LAA of MVD and non-MVD (that is,
heart failure) patients. In fact, only heart failure patients (n  4)
showed a significant increase in right atrial appendage (RAA)
vWF expression compared with other cardiac patients, but all of
the heart failure specimens were obtained postmortem, whereas all
other cardiac patient specimens were obtained during cardiac
surgery. Perhaps the main finding that can be truly relied upon was
the detection of a significant difference between LAA and RAA
levels of vWF expression in patients with MVD, with greater levels
of vWF in the LAA endocardium compared to the RAA. This
finding, coupled with the reported correlation between increased
levels of vWF expression and the degree of observed platelet
adhesion, could suggest a mechanism for left atrial (LA) thrombus
development, which is associated with mitral stenosis.
Unfortunately, Fukuchi et al. (1) do not clarify the proportion of
MVD patients with mitral stenosis or mitral incompetence, as
mitral incompetence is believed to be associated with a reduction in
risk of intra-atrial thrombogenesis. In a study using scanning
electron microscopy (SEM), we recently reported evidence of more
advanced endocardial changes in the LAA compared with the
RAA in MVD patients, and among specimens from patients with
mitral stenosis when compared to those with mitral incompetence
(2). Furthermore, increasing plasma levels of vWF, an established
plasma marker of endothelial damage/dysfunction, were seen to
correlate with more advanced SEM endocardial changes. There
was also a nonsignificant trend toward increased endocardial
changes in MVD patients with AF compared to sinus rhythm.
Because AF was present in 12 of the 15 MVD patients studied by
Fukuchi et al. (1), the possibility arises that the presence of AF
itself (or, at least, in combination with mitral stenosis) led to the
increase in LAA expression of vWF in their study.
Fukuchi et al. (1) state that the presence of AF appeared not to
influence the LAA expression of vWF, but this is based on only
four specimens obtained from patients in sinus rhythm, of which at
least one was from a postmortem specimen without MVD. In
contrast, all 12 LAA specimens from the AF group were taken
from live patients with MVD during a Maze procedure; thus, the
comparison may be underpowered and poorly standardized. Sec-
ond, although the comparison of RAA vWF levels was more
appropriately powered, standardization between the two groups
was again poor, with 12 out of a total of 16 AF patients studied
having MVD, compared with only 3 out of 27 sinus rhythm
patients. Furthermore, because the LAA is the main site of
thrombogenesis in patients with AF, the lack of observed RAA
changes may be of limited clinical significance.
Atrial fibrillation, with or without the additional presence of
MVD, has been shown to be associated with increased levels of
circulating plasma vWF, as well as other markers of thrombogen-
esis and platelet activation (3). We have demonstrated that
peripheral levels of vWF have been shown to be similar to
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intra-atrial levels in patients with AF and mitral stenosis (4), and
furthermore, elevated levels of vWF in peripheral blood have been
shown to independently predict the presence of LAA thrombus
visible by transesophageal echocardiography (5). One preliminary
report found increased LAA and RAA endocardial expression of
vWF, as well as increased expression of tissue factor in atrial
macrophages in AF, compared to sinus rhythm (6).
It is an exciting possibility, however, that plasma levels of vWF
may be a reflection of increased atrial endocardial production,
possibly in association with damaged endocardial integrity and
subsequent release into the blood pool, which itself may predispose
to intra-atrial thrombus formation. Indeed, plasma levels of vWF
are significantly correlated with fibrin D-dimer levels, an index of
thrombogenesis in patients with AF (7). The possibility arises that
plasma vWF may provide prognostic information regarding
thrombogenesis and risk of subsequent thromboembolism and
stroke in AF, and levels of hemostatic markers could potentially be
used for risk-stratification purposes and guiding appropriate anti-
thrombotic therapy; prospective longitudinal studies would be
required to evaluate this possibility.
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REPLY
We appreciate the comments by Drs. Conway and Lip on our
current study (1). Basically, our data on immunoreactive von
Willebrand factor (vWF) in the atrial endocardium are not directly
comparable with the data on plasma vWF levels (2,3). Because the
latter would reflect some variable factors: that is, endothelial cell-
or platelet-origin, constitutive secretion or leakage from damaged
cells, and the cause or result of thrombogenesis? However, several
points raised in the letter may be important for understanding our
data. The first point is related to vWF immunostaining in
postmortem atrial tissue. Our study had a limitation in the tissue
sampling at heart surgery as described in the Methods section. For
comparison, atrial tissue was also obtained at autopsy from heart
failure patients and noncardiac patients. The endocardial endothelium
showed similar staining for endothelial cell marker CD31, but quite
different vWF staining between heart failure patients and noncardiac
patients. In addition, the apparent vWF staining in the endothelium
of intramyocardial vessels was preserved in all postmortem tissues as
seen in the operative tissues (see our Fig. 2). Therefore, there is no
reason to consider the data on the postmortem tissue to be weak.
The second point is related to the proportion of patients with
mitral stenosis or mitral regurgitation. Strong vWF staining in the
endocardium of left atrial appendage was seen in all 10 patients
examined, irrespective of mitral stenosis or mitral regurgitation
(five patients each). Although the vWF levels in the endocardium
may not necessarily reflect a hypercoagulable state in mitral
stenosis compared with that in mitral regurgitation, it must be
recognized that vWF in the endocardium is only one of the factors
involved in intra-atrial thrombogenesis.
The third point is related to the interrelation between atrial
fibrillation (AF) and underlying heart disease in intra-atrial thro-
mogenesis. In mitral valvular disease, AF often occurs secondarily
to increased mechanical stress to the left atrial wall. It is well
known that thromboembolic events occur more frequently in AF
patients with underlying heart diseases than in patients with AF
alone. Our study showed much stronger vWF staining in the left
atrial endocardium than in the right one of AF patients with mitral
valvular disease (see our Figs. 1 and 3). In addition, immunoreac-
tive vWF in the right atrial endocardium of cardiac but non-AF
patients was significantly increased compared with that of noncar-
diac patients (see our Fig. 3). Because the conditions of all cardiac
patients examined were severe enough to require heart surgery, the
atrial wall may have been exposed to overloaded conditions. Thus,
we speculate that increased vWF in the endocardium may be
associated with mechanical stress to the atrial wall, irrespective of
whether AF is present or not. Increased vWF in the endocardium via
mediating platelet adhesion to the endocardium would be of limited
significance in thrombogenesis. Probably, rheologic factors induced by
AF in combination with underlying heart disease are required for the
development of thrombi responsible for embolic events (4).
Finally, we emphasize that immunoreactive vWF in the atrial
endocardium was increased in patients with severe underlying
heart diseases regardless of the presence of AF. This may be
important particularly in regulating local thrombogenicity on the
endocardial surface.
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